Neuromeka Balance Sheet Health
Financial Health criteria checks 3/6
Neuromeka has a total shareholder equity of ₩18.5B and total debt of ₩38.3B, which brings its debt-to-equity ratio to 207%. Its total assets and total liabilities are ₩91.0B and ₩72.4B respectively.
Key information
207.0%
Debt to equity ratio
₩38.34b
Debt
Interest coverage ratio | n/a |
Cash | ₩33.36b |
Equity | ₩18.52b |
Total liabilities | ₩72.45b |
Total assets | ₩90.97b |
Financial Position Analysis
Short Term Liabilities: A348340's short term assets (₩50.6B) do not cover its short term liabilities (₩51.9B).
Long Term Liabilities: A348340's short term assets (₩50.6B) exceed its long term liabilities (₩20.6B).
Debt to Equity History and Analysis
Debt Level: A348340's net debt to equity ratio (26.9%) is considered satisfactory.
Reducing Debt: A348340 had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A348340 has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: A348340 has less than a year of cash runway if free cash flow continues to reduce at historical rates of 41.9% each year